<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04417569</url>
  </required_header>
  <id_info>
    <org_study_id>2002-ABU-001-CC</org_study_id>
    <nct_id>NCT04417569</nct_id>
  </id_info>
  <brief_title>A Proof of Concept Study of Serum Progesterone Levels for IVF/ICSI Following HCG Trigger for Oocyte Maturation</brief_title>
  <official_title>A Proof of Concept Study of Serum Progesterone Levels in Spontaneous Ovulatory Menstrual Cycles and Stimulatory Cycles for IVF and ICSI Following HCG Trigger for Oocyte Maturation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Middle East Fertility Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Middle East Fertility Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare serum progesterone levels in spontaneous ovulatory menstrual cycles
      and serum progesterone levels post hCG (human chorionic gonadotropin) trigger in stimulated
      cycles for IVF (in vitro fertilisation) /ICSI (Intracytoplasmic sperm injection).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have suggested that controlled ovarian hyperstimulation adversely affects endometrial
      receptivity. In ovarian stimulation cycles with exogenous gonadotrophins there is an ongoing
      debate regarding the effect of a late follicular phase progesterone level on reproductive
      outcomes. It is not yet clarified if an elevated serum progesterone level in the late
      follicular phase is a symptom or cause of an adverse effect on reproductive outcomes. A new
      hypothesis is evolving and gaining momentum providing a novel explanation for the association
      between late follicular phase progesterone rise and reproductive outcome. It is proposed that
      exogenous FSH (Follicle-stimulating hormone) administration results in supraphysiological
      levels of FSH, which induce an abundance of LH (luteinizing hormone) receptors on granulosa
      cells causing the follicles to become hypersensitive to LH-like activity (ie hCG trigger).
      Based on this hypothesis, the focus should be placed on the hCG trigger rather than on the
      late follicular phase progesterone rise.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Level of progesterone</measure>
    <time_frame>2 days</time_frame>
    <description>serum progesterone levels in spontaneous ovulatory menstrual cycles and serum progesterone levels post human chorionic gonadotrophin (hCG) trigger in stimulated cycles for IVF/ICSI will be compared</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days until ovulation in spontaneous natural cycles</measure>
    <time_frame>16 days</time_frame>
    <description>The number of day until ovulation will be described as a qualitative variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline of estrogen levels at time of ovulation in spontaneous natural cycles</measure>
    <time_frame>3 days</time_frame>
    <description>The decline of estrogen will be measure at the three different times for the spontaneous ovulatory menstrual cycle and compared among the three times using a t test dependent sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rise of levels at time of ovulation in spontaneous natural cycles</measure>
    <time_frame>3 days</time_frame>
    <description>The rise of LH levels will be measured at the three different times for the spontaneous ovulatory menstrual cycle and compared among the three times using a t test dependent sample.
Rise of progesterone levels will be measured at the three different times for the spontaneous ovulatory menstrual cycle and compared among the three times using a t test dependent sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>7 days</time_frame>
    <description>to compare endometrial thickness measurement on the day of confirmed ovulation (day 0) and on the day of embryo transfer (day 5)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Infertility</condition>
  <condition>Infertility, Female</condition>
  <condition>IVF</condition>
  <condition>hCG</condition>
  <arm_group>
    <arm_group_label>stimulated cycles</arm_group_label>
    <description>Patients will have blood drawn on three separate occasions following hCG trigger on the day of final oocyte maturation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>spontaneous cycles</arm_group_label>
    <description>Commencing on the second day of menses and intermittently throughout the patients' natural cycle ultrasound scans will be performed to monitor follicular growth.
In conjunction with ultrasound monitoring the patient will undergo serial measurements of serum LH, estradiol and progesterone levels to accurately determine the timing of ovulation. These serum hormonal levels will be measured with an automated ElecsysÂ® immunoanalyzer (Roche Diagnostics, Mannheim, Germany).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>human chorionic gonadotropin</description>
    <arm_group_label>spontaneous cycles</arm_group_label>
    <arm_group_label>stimulated cycles</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Endometrial thickness monitoring</description>
    <arm_group_label>spontaneous cycles</arm_group_label>
    <arm_group_label>stimulated cycles</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Progesterone, Luteinizing Hormone</description>
    <arm_group_label>spontaneous cycles</arm_group_label>
    <arm_group_label>stimulated cycles</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients who are planned to commence ovarian stimulation for IVF/ICSI with hCG
        trigger for oocyte maturation and plan to avail of pre-implantation genetic screening with
        embryo vitrification of their biopsied embryos at blastocyst stage
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females aged 18 to 42 years with regular menstrual cycles of 26-34 days

          -  Undergoing ovarian stimulation for IVF/ICSI &amp; PGS.

          -  Receiving recombinant FSH for stimulation

          -  hCG 5000iu IM as trigger injection for oocyte maturation.

          -  Ovarian stimulation in GnRH-antagonist protocols

          -  BMI 18- 35 kg/m2

          -  Having 1 or 2 euploid embryos for transfer in spontaneous natural cycles.

        Exclusion Criteria:

          -  Poor ovarian reserve as defined by Bologna criteria

          -  PCOS in accordance with Rotterdam criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Coughlan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Middle East Fertility Clinic LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Lawrenz, PhD</last_name>
    <phone>+97126528000</phone>
    <phone_ext>1108</phone_ext>
    <email>barbara.lawrenz@ivirma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shieryl Digma, RN</last_name>
    <phone>+97126528000</phone>
    <phone_ext>1122</phone_ext>
    <email>shieryl.digma@ivirma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVI Middle East Fertility Clinic</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>60202</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <contact>
      <last_name>Barbara Lawrenz, PhD</last_name>
      <phone>+97102 652 8000</phone>
      <phone_ext>1108</phone_ext>
      <email>barbara.lawrenz@ivirma.com</email>
    </contact>
    <contact_backup>
      <last_name>Shieryl Digma, RN</last_name>
      <phone>+97102 652 8000</phone>
      <phone_ext>1122</phone_ext>
      <email>shieryl.digma@ivirma.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <results_reference>
    <citation>Bourgain C, Devroey P. The endometrium in stimulated cycles for IVF. Hum Reprod Update. 2003 Nov-Dec;9(6):515-22. Review.</citation>
    <PMID>14714588</PMID>
  </results_reference>
  <results_reference>
    <citation>Devroey P, Bourgain C, Macklon NS, Fauser BC. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab. 2004 Mar;15(2):84-90. Review.</citation>
    <PMID>15036255</PMID>
  </results_reference>
  <results_reference>
    <citation>Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, Devroey P. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril. 2002 Nov;78(5):1025-9.</citation>
    <PMID>12413988</PMID>
  </results_reference>
  <results_reference>
    <citation>Nikas G, Develioglu OH, Toner JP, Jones HW Jr. Endometrial pinopodes indicate a shift in the window of receptivity in IVF cycles. Hum Reprod. 1999 Mar;14(3):787-92.</citation>
    <PMID>10221715</PMID>
  </results_reference>
  <results_reference>
    <citation>SimÃ³n C, Garcia Velasco JJ, Valbuena D, Peinado JA, Moreno C, RemohÃ­ J, Pellicer A. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen. Fertil Steril. 1998 Aug;70(2):234-9.</citation>
    <PMID>9696213</PMID>
  </results_reference>
  <results_reference>
    <citation>Weinerman R, Mainigi M. Why we should transfer frozen instead of fresh embryos: the translational rationale. Fertil Steril. 2014 Jul;102(1):10-8. doi: 10.1016/j.fertnstert.2014.05.019. Epub 2014 Jun 2. Review.</citation>
    <PMID>24890274</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu Y, Lee KF, Ng EH, Yeung WS, Ho PC. Gene expression profiling of human peri-implantation endometria between natural and stimulated cycles. Fertil Steril. 2008 Dec;90(6):2152-64. doi: 10.1016/j.fertnstert.2007.10.020. Epub 2008 Jan 14.</citation>
    <PMID>18191855</PMID>
  </results_reference>
  <results_reference>
    <citation>Haouzi D, Assou S, Mahmoud K, Tondeur S, RÃ¨me T, Hedon B, De Vos J, Hamamah S. Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients. Hum Reprod. 2009 Jun;24(6):1436-45. doi: 10.1093/humrep/dep039. Epub 2009 Feb 26.</citation>
    <PMID>19246470</PMID>
  </results_reference>
  <results_reference>
    <citation>Roque M, Lattes K, Serra S, SolÃ  I, Geber S, Carreras R, Checa MA. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril. 2013 Jan;99(1):156-62. doi: 10.1016/j.fertnstert.2012.09.003. Epub 2012 Oct 3. Review.</citation>
    <PMID>23040524</PMID>
  </results_reference>
  <results_reference>
    <citation>Roque M, Valle M, GuimarÃ£es F, Sampaio M, Geber S. Freeze-all policy: fresh vs. frozen-thawed embryo transfer. Fertil Steril. 2015 May;103(5):1190-3. doi: 10.1016/j.fertnstert.2015.01.045. Epub 2015 Mar 4.</citation>
    <PMID>25747130</PMID>
  </results_reference>
  <results_reference>
    <citation>Haas J, Smith R, Zilberberg E, Nayot D, Meriano J, Barzilay E, Casper RF. Endometrial compaction (decreased thickness) in response to progesterone results in optimal pregnancy outcome in frozen-thawed embryo transfers. Fertil Steril. 2019 Sep;112(3):503-509.e1. doi: 10.1016/j.fertnstert.2019.05.001. Epub 2019 Jun 24.</citation>
    <PMID>31248618</PMID>
  </results_reference>
  <results_reference>
    <citation>Testart J, Frydman R, Feinstein MC, Thebault A, Roger M, Scholler R. Interpretation of plasma luteinizing hormone assay for the collection of mature oocytes from women: definition of a luteinizing hormone surge-initiating rise. Fertil Steril. 1981 Jul;36(1):50-4.</citation>
    <PMID>7250407</PMID>
  </results_reference>
  <results_reference>
    <citation>Irani M, Robles A, Gunnala V, Reichman D, Rosenwaks Z. Optimal parameters for determining the LH surge in natural cycle frozen-thawed embryo transfers. J Ovarian Res. 2017 Oct 16;10(1):70. doi: 10.1186/s13048-017-0367-7.</citation>
    <PMID>29037231</PMID>
  </results_reference>
  <results_reference>
    <citation>Groenewoud ER, Macklon NS, Cohlen BJ; ANTARCTICA Study Group. The effect of elevated progesterone levels before HCG triggering in modified natural cycle frozen-thawed embryo transfer cycles. Reprod Biomed Online. 2017 May;34(5):546-554. doi: 10.1016/j.rbmo.2017.02.008. Epub 2017 Feb 28.</citation>
    <PMID>28319018</PMID>
  </results_reference>
  <results_reference>
    <citation>Fatemi HM, Kyrou D, Bourgain C, Van den Abbeel E, Griesinger G, Devroey P. Cryopreserved-thawed human embryo transfer: spontaneous natural cycle is superior to human chorionic gonadotropin-induced natural cycle. Fertil Steril. 2010 Nov;94(6):2054-8. doi: 10.1016/j.fertnstert.2009.11.036. Epub 2010 Jan 25.</citation>
    <PMID>20097333</PMID>
  </results_reference>
  <results_reference>
    <citation>Bosch E, Labarta E, Crespo J, SimÃ³n C, RemohÃ­ J, Jenkins J, Pellicer A. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod. 2010 Aug;25(8):2092-100. doi: 10.1093/humrep/deq125. Epub 2010 Jun 10.</citation>
    <PMID>20539042</PMID>
  </results_reference>
  <results_reference>
    <citation>Griesinger G, Mannaerts B, Andersen CY, Witjes H, Kolibianakis EM, Gordon K. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertil Steril. 2013 Dec;100(6):1622-8.e1-3. doi: 10.1016/j.fertnstert.2013.08.045. Epub 2013 Sep 29.</citation>
    <PMID>24083873</PMID>
  </results_reference>
  <results_reference>
    <citation>Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update. 2013 Sep-Oct;19(5):433-57. doi: 10.1093/humupd/dmt014. Epub 2013 Jul 4.</citation>
    <PMID>23827986</PMID>
  </results_reference>
  <results_reference>
    <citation>Yding Andersen C, Bungum L, Nyboe Andersen A, Humaidan P. Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate. Reprod Biomed Online. 2011 Aug;23(2):187-95. doi: 10.1016/j.rbmo.2011.04.003. Epub 2011 Apr 28.</citation>
    <PMID>21665546</PMID>
  </results_reference>
  <results_reference>
    <citation>Friis Wang N, Skouby SO, Humaidan P, Andersen CY. Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise. Hum Reprod. 2019 May 1;34(5):942-948. doi: 10.1093/humrep/dez023.</citation>
    <PMID>30927415</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

